RetinalGeniX Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

A New Patent Granted for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes. It is an objective of this invention to visualize naturally unfolded and misfolded proteins in eye tissues, as well as other biological material, and to detect their structures and molecular mechanisms underlying their involvement in diseases.

The invention can identify changes in the geography of the eye, including atrophy, emaciation, and swelling. Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc. Each of these conditions is typically caused by one or more diseases, and being able to visualize and measure these conditions in the eye provides very useful information regarding the cause, extent, and diagnosis of various diseases of the body.

The Company believes that various conformational diseases of the body may be detected early on by finding trace elements of their existence by visualizing the anatomy of the eye. Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina. 

Conformational diseases include more than 40 disorders, including Alzheimer's, Parkinson's, and Huntington's Disease, as well as Cystic Fibrosis and some forms of cancer, liver, heart, and kidney disease and are typically caused by the accumulation of unfolded or misfolded proteins. 

As an example, Alzheimer's disease is characterized by an increase of tiny inclusions in the nerve tissue, called plaques. These plaques are found between the dying cells in the brain from the build-up of a protein called beta-amyloid. Beta-amyloid protein has been found to aggregate in the lens of the eye. Accordingly, the ability to detect and measure beta-amyloid aggregates in the eye creates an opportunity to detect and diagnose the onset of Alzheimer's disease.